Dipeptidyl peptidase 4 inhibitor-associated mucous membrane pemphigoid.
BP180
DPP-4
diabetes
mucous membrane pemphigoid
type 17 collagen
Journal
The Journal of dermatology
ISSN: 1346-8138
Titre abrégé: J Dermatol
Pays: England
ID NLM: 7600545
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
24
02
2021
accepted:
20
06
2021
pubmed:
16
7
2021
medline:
6
10
2021
entrez:
15
7
2021
Statut:
ppublish
Résumé
Dipeptidyl peptidase 4 inhibitors (DPP-4i) are associated with an increased risk of developing bullous pemphigoid (BP) in patients with diabetes. Autoantibodies targeting epitopes on the processed BP180, 120-kDa (LAD-1), and 97-kDa (LABD97) linear immunoglobulin (Ig)A dermatosis antigens are the major autoantibodies in DPP-4i-associated BP. However, no case of mucous membrane pemphigoid (MMP) developing during treatment with DPP-4i has been reported. We report a case of MMP associated with DPP-4i. A man in his late 70s presented with oral mucous membrane erosion and a few blisters on his upper chest and back. He had used linagliptin for diabetes for over 1 year when he presented. The immunological characteristics were similar to DPP4i-associated BP: higher reactivity to LAD-1 and LABD97 than to the full-length BP180. The aphthae achieved remission after oral linagliptin was replaced with sitagliptin. However, 6 months later, the aphthae relapsed and any DPP-4i was discontinued. The aphthae disappeared, and now he is completely free from lesions associated with MMP. This case suggests that the DPP-4i may have shared roles in the production of IgG antibodies to LAD-1 or to LABD97 in the pathogenesis of DPP-4i-associated BP and MMP. Our case highlights the possibility of overlooking the mild MMP in DPP-4i-treated diabetes patients with mucosal lesions.
Identifiants
pubmed: 34265108
doi: 10.1111/1346-8138.16061
doi:
Substances chimiques
Dipeptidyl-Peptidase IV Inhibitors
0
Linagliptin
3X29ZEJ4R2
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1584-1587Informations de copyright
© 2021 Japanese Dermatological Association.
Références
Kridin K, Bergman R. Association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors in patients with diabetes: estimating the risk of the new agents and characterizing the patients. JAMA Dermatol. 2018;154:1152-8.
Mai Y, Nishie W, Izumi K, Shimizu H. Preferential reactivity of dipeptidyl peptidase-IV inhibitor-associated bullous pemphigoid autoantibodies to the processed extracellular domains of BP180. Front Immunol. 2019;10:1224.
Horikawa H, Kurihara Y, Funakoshi T, Umegaki-Arao N, Takahashi H, Kubo A, et al. Unique clinical and serological features of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors. Br J Dermatol. 2018;178:1462-3.
Lee SG, Lee HJ, Yoon MS, Kim DH. Association of dipeptidyl peptidase 4 inhibitor use with risk of bullous pemphigoid in patients with diabetes. JAMA Dermatol. 2019;155:172-7.
Schmidt E, Skrobek C, Kromminga A, Hashimoto T, Messer G, Brocker E-B, et al. Cicatricial pemphigoid: IgA and IgG autoantibodies target epitopes on both intra- and extracellular domains of bullous pemphigoid antigen 180. Br J Dermatol. 2001;145:778-83.
Leverkus M, Georgi M, Zhuxiang N, Hashimoto T, Bröcker E-B, Zillikens D. Cicatricial pemphigoid with circulating IgA and IgG autoantibodies to the central portion of the BP180 ectodomain: Beneficial effect of adjuvant therapy with high-dose intravenous immunoglobulin. J Am Acad Dermatol. 2002;46:116-22.
Choi Y, Lee SE, Fukuda S, Hashimoto T, Kim S-C. Mucous membrane pemphigoid with immunoglobulin G autoantibodies against full-length and 120-kDa ectodomain of BP180. J Dermatol. 2011;38:169-72.